The association of weight status with glycemic control, diabetes related complications and anti-hyperglycemic medication use in patients with type 2 diabetes mellitus: The results of the Australian National Diabetes Audit (Australian National Diabetes Audits (ANDA)) 2015–2022
Authors' conclusion
Patients with T2DM and obesity have poorer glycemic control, higher utilisation of anti-glycemic medications and greater odds of diabetes related complications. Approaches to optimise glycemic control that also deliver weight reduction should be an integral component of diabetes management to help improve health outcomes for people with T2DM.
Study context
- Population
- Adults with T2DM in the Australian National Diabetes Audits (ANDA) 2015–2022; 55.7 % male, mean BMI 33.4 kg/m²
- Participants
- 13,589 adults
- Exposure
- Obesity vs non-obesity weight status
- Outcome
- Association of weight status with glycemic control (HbA1c categories)
Methodological detailsnational audit data 2015–2022
- National audit data 2015–2022
Main finding
As reported in the abstract
Above-target glycemia by weight status
ObesityOdds ratio (95 % CI)
Moderately above target (HbA1c 7.1-9 %)
1.20(1.05–1.37)
Greatly above target (HbA1c > 9 %)
1.43(1.22–1.68)
- Above-target glycemia (HbA1c > 7 %), all patients
- 71 %
Observational data: associations, not effects.
Further findings
Diabetes complications and anti-hyperglycemic drug use
- Patients with obesity more likely to have CVD, DFU and peripheral vascular disease, despite use of a greater number of anti-hyperglycemic drugs
Original publication
The association of weight status with glycemic control, diabetes related complications and anti-hyperglycemic medication use in patients with type 2 diabetes mellitus: The results of the Australian National Diabetes Audit (ANDA) 2015–2022. Diabetes Res Clin Pract. Published 20 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →